Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Conditions

Sarcoma 9Rhabdomyosarcoma 7Wilms Tumor 6Malignant mesenchymal tumor 6Ovarian Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Melanoma 2Liposarcoma 2Kidney Neoplasms 2Hydatidiform Mole 2Hemangiosarcoma 2Hemangiopericytoma, Malignant 2Fibrosarcoma 2Desmoplastic Small Round Cell Tumor 2Testicular Neoplasms 1Teratoma, Ovarian 1Sarcoma, Ewing 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Gestational Trophoblastic Disease 1Choriocarcinoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Blast Crisis 1Beckwith-Wiedemann Syndrome 1

Interventions

Methotrexate 3merphos 2Dactinomycin 2Vitamin B Complex 1Pemetrexed 1Leucovorin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hydatidiform Mole × Dactinomycin × Clear all
NCT01535053 2022-08-12

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
57 enrolled 12 charts

Choriocarcinoma, Hydatidiform Mole

NCT00003702 2018-05-15

Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
240 enrolled 9 charts

Hydatidiform Mole

Data powered by HemOnc (CC BY 4.0) Colophon âš¡